People · Operator
Named in public records as an officer, director or promoter · active 2013–2016 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zavante Therapeutics, Inc. | — | Pharmaceuticals | Series C | $60.2M | $1.6B | 2016 |
| Kalyra Pharmaceuticals, Inc. | — | Biotechnology | Series A | $11.4M | $223.5M | 2013 |
Cam L. Gallagher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Cam L. Gallagher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Cam L. Garner | 2 | 11 |
| Scott L. Glenn | 1 | 9 |
| Theodore R. Schroeder | 1 | 4 |
| Cam R. Gallagher | 1 | 2 |
| Kevin D. Bunker | 1 | 1 |
| Michael E. Breede | 1 | 1 |
| Patrick L. Heron | 1 | 1 |
| Kevin L. Finney | 1 | 1 |
| David L. Hirsch | 1 | 1 |
| Evelyn J. Ellis-Grosse | 1 | 1 |
| Cam R. Garner | 1 | 1 |
| Ned A. Israelsen | 1 | 1 |
| Dirk A. Thye | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.